Quantum Cyber (QUCY)
NASDAQ:QUCY
Want to see QUCY full AI Analyst Report?
Top Page
Quantum Cyber
(NASDAQ:QUCY)
Select Model
Select Model
Rating:50Neutral
Price Target:
$2.50
▲(115.52% Upside)
Action:Reiterated
Date:05/20/26
The score is held down primarily by weak financial performance (persistent losses, heavy cash burn, and deteriorating leverage). Technicals provide the main support via strong momentum and price strength, while valuation is constrained by ongoing losses and corporate events are mixed due to financing flexibility offset by dilution and listing-compliance risk.
Positive Factors
Material gross margin improvement
A large, multi-year rise in gross margin indicates significantly improved unit economics and product-level profitability. This strengthens long-term scalability: if revenue stabilizes, higher gross margins provide room to absorb fixed costs and move toward operating leverage and eventual cash generation.
Negative Factors
Persistent cash burn and negative free cash flow
Sustained, large negative operating and free cash flows indicate the business is not self-funding growth. Persistent cash burn forces repeated external financing, increases dilution risk, limits investment in commercialization, and creates execution uncertainty until consistent positive cash generation is achieved.
Read all positive and negative factors
Positive Factors
Negative Factors
Material gross margin improvement
A large, multi-year rise in gross margin indicates significantly improved unit economics and product-level profitability. This strengthens long-term scalability: if revenue stabilizes, higher gross margins provide room to absorb fixed costs and move toward operating leverage and eventual cash generation.
Read all positive factors
Quantum Cyber (QUCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$41.30M
Dividend YieldN/A
Average Volume (3M)350.23K
Price to Earnings (P/E)―
Beta (1Y)1.15
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees26
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-3.08
Shares Outstanding12,515,336
10 Day Avg. Volume923,862
30 Day Avg. Volume350,228
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)7.48
Price to Sales (P/S)8.93
P/FCF Ratio-0.40
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue117.39
Enterprise Value/Gross Profit-108.46
Enterprise Value/Ebitda-3.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$917.75K
Quantum Cyber Business Overview & Revenue Model
Company Description
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product p...
How the Company Makes Money
null...
Quantum Cyber Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
24
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 286.72K | 537.08K | 893.99K | 895.48K | 529.88K | 577.35K |
| Gross Profit | -310.34K | 389.79K | 574.88K | 509.66K | 182.15K | 177.62K |
| EBITDA | -10.21M | -15.22M | -19.56M | -24.87M | -25.72M | -11.28M |
| Net Income | -13.43M | -16.21M | -21.65M | -26.30M | -26.39M | -11.69M |
Balance Sheet | ||||||
| Total Assets | 7.72M | 5.33M | 13.24M | 15.41M | 20.24M | 10.04M |
| Cash, Cash Equivalents and Short-Term Investments | 4.45M | 889.09K | 6.24M | 7.07M | 17.14M | 8.73M |
| Total Debt | 126.79K | 2.57M | 3.27M | 7.42M | 3.23M | 2.58M |
| Total Liabilities | 3.13M | 4.69M | 7.19M | 12.16M | 6.14M | 3.68M |
| Stockholders Equity | 4.59M | 641.60K | 6.05M | 3.25M | 14.10M | 6.36M |
Cash Flow | ||||||
| Free Cash Flow | -9.23M | -12.03M | -17.34M | -23.84M | -15.43M | -3.24M |
| Operating Cash Flow | -9.22M | -10.98M | -17.09M | -21.94M | -14.77M | -3.22M |
| Investing Cash Flow | -1.10M | -1.03M | -198.82K | -1.90M | -658.48K | 1.20M |
| Financing Cash Flow | 9.94M | 6.76M | 16.60M | 14.23M | 23.94M | 10.61M |
Quantum Cyber Technical Analysis
Positive
1.16
Price Trends
0.73
Positive
0.87
Positive
1.16
Positive
Market Momentum
0.57
Negative
69.85
Neutral
60.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QUCY, the sentiment is Positive. The current price of 1.16 is above the 20-day moving average (MA) of 1.00, above the 50-day MA of 0.73, and above the 200-day MA of 1.16, indicating a bullish trend. The MACD of 0.57 indicates Negative momentum. The RSI at 69.85 is Neutral, neither overbought nor oversold. The STOCH value of 60.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QUCY.
Quantum Cyber Risk Analysis
Quantum Cyber disclosed 40 risk factors in its most recent earnings report. Quantum Cyber reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Nasdaq maintains certain standards which Nasdaq requires listed companies meet for their respective securities to continue to be listed and traded on its exchange, and if we are unable to continue to meet such continued listing requirements, Nasdaq may choose to delist our ordinary shares from its exchange, which may adversely affect the liquidity and trading price of our ordinary shares. Q4, 2023
2.
We are subject to cybersecurity risks to operational systems, security systems, infrastructure and personal data processed by us or third-party vendors or suppliers and any material failure, weakness, interruption, cyber event, incident or breach of security could prevent us from effectively operating our business or subject us to liability for mishandling sensitive data. Q4, 2023
Quantum Cyber Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $8.73M | -0.47 | -174.16% | ― | 33.26% | 49.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $41.30M | -0.30 | -465.82% | ― | ― | ― | |
44 Neutral | $6.87M | -1.06 | -537.60% | ― | ― | 98.32% | |
41 Neutral | $5.17M | ― | -496.37% | ― | -87.25% | 87.10% |
* Healthcare Sector Average
QUCY
Quantum Cyber
2.52
0.19
8.15%
NDRA
ENDRA Life Sciences
5.59
2.49
80.32%
INBS
Intelligent Bio Solutions
3.29
-9.51
-74.30%
ISPC
iSpecimen
3.67
-43.33
-92.19%
BGLC
BioNexus Gene Lab Corp
2.10
-0.68
-24.46%
Quantum Cyber Corporate Events
Business Operations and StrategyExecutive/Board Changes
Quantum Cyber Appoints New Director to Strengthen Governance
Positive
May 18, 2026
On May 12, 2026, Quantum Cyber N.V. entered into an Advisory Agreement with Alexander Gurevich, appointing him as an independent advisor for a 12‑month term to guide strategic transactions, in exchange for 5 million restricted shares and exp...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Quantum Cyber Expands Equity Program and CFO Agreement
Positive
May 8, 2026
On May 4, 2026, Quantum Cyber N.V. amended its equity distribution agreement with Maxim Group LLC, increasing the maximum aggregate amount of ordinary shares that may be sold under the program from $10 million to $100 million, significantly expand...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingShareholder MeetingsStock Split
Quantum Cyber N.V. completes major financing and governance overhaul
Neutral
Apr 28, 2026
On February 13, 2026, Quantum Cyber entered into a $6 million private placement with investor David E. Lazar, issuing series A, B and C preferred shares on February 17, 2026 for $3 million and completing the second closing for series D and E prefe...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
Quantum Cyber Divests ColoAlert IP, Refocuses on Pancreatic Screening
Positive
Apr 15, 2026
In February 2026, Quantum Cyber’s board decided to wind down its ColoAlert colorectal cancer screening business and halt development of its next-generation colorectal cancer screening candidates, terminating staff primarily dedicated to thos...
Delistings and Listing ChangesRegulatory Filings and Compliance
Mainz Biomed Receives Nasdaq Notice on Bid Price
Negative
Mar 25, 2026
On March 20, 2026, Mainz Biomed N.V. disclosed that it had received a notice from Nasdaq’s Listing Qualifications Department stating that the company’s ordinary shares failed to meet the $1.00 minimum bid price requirement for 30 conse...
Business Operations and StrategyPrivate Placements and Financing
Quantum Cyber Aligns Strategy With U.S. Cyber Priorities
Positive
Mar 17, 2026
On March 17, 2026, Quantum Cyber announced that it is aligning its strategy with the Trump Administration’s new National Cybersecurity Strategy and is actively evaluating acquisitions in quantum computing, post-quantum cryptography, zero-tru...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.